Project Grant R01CA278939
Award Date
9/4/24
Completion Date
8/31/29
Dollars Obligated
$1.2M
Federal Agency
National Cancer Institute
Federal Grant Program
93.393
Assistance Type
Project Grant
Place of Performance
Baltimore, MD 21201, USA
Similar Awards
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $391,325.00 to the University of Arizona to develop a new portable confocal microscope that can rapidly image Meissner's corpuscles, which are microscopic nerve endings associated with chemotherapy-induced peripheral neuropathy (CIPN). The goals are to evaluate the clinical utility of this portable confocal microscopy (PCM) technology for assessing CIPN, and to develop deep...
This $255,769 Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) supports the development of a novel proxy-report survey to screen for chemotherapy-induced peripheral neuropathy (CIPN) in young children aged 1-5 years. The grant recipient, Yale University, will 1) use qualitative research methods to develop survey items to screen for CIPN symptoms, 2) prospectively evaluate the survey's psychometric properties, and 3) collect preliminary...
This federal Project Grant award from the National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), provides $181,448 to Virginia Commonwealth University (VCU) to research the use of the NLRP3 inflammasome inhibitor dapansutrile for treating chemotherapy-induced peripheral neuropathy (CIPN). The project aims to determine if dapansutrile can alleviate and prevent CIPN caused by paclitaxel and cisplatin chemotherapy in mouse models, including both naive and...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $816,554 to The University of Texas MD Anderson Cancer Center to develop and validate a mouse model of chemotherapy-induced peripheral neuropathy (CIPN) in the context of colorectal cancer. The project aims to assess the impact of tumor growth and surgical resection on the subsequent development of pain hypersensitivity in...
The National Cancer Institute (NCI) awarded a Project Grant (CFDA 93.395 - Cancer Treatment Research) to the Board of Regents of the University of Nebraska's University of Nebraska Medical Center (UNMC) Division. The $179,403 grant, awarded on April 1, 2025, will fund research to develop novel flupirtine analogue compounds that can effectively relieve chemotherapy-induced neuropathic pain (CINP) in cancer patients while addressing the safety concerns associated with the parent flupirtine...
This federal Project Grant award, R01CA273001, was provided by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395). The $402,874 award will fund research at the University of Texas Medical Branch at Galveston (UTMB) to investigate the mechanisms underlying paclitaxel-induced peripheral neuropathy (PIPN), a significant adverse effect experienced by cancer patients receiving paclitaxel infusion. The research aims to determine if the acute over-excitation...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides $661,122 in funding to The Trustees of Columbia University in the City of New York to investigate the pathogenic role of tubulin post-translational modifications in chemotherapy-induced peripheral neuropathy (CIPN). The research aims to evaluate whether the accumulation of delta-2 tubulin, an irreversible tubulin modification, plays a common pathogenic role in the neuropathic...
This $419,474 project grant from the National Cancer Institute, part of the Department of Health and Human Services, supports research under the Cancer Treatment Research program to develop mechanism-based strategies to treat chemotherapy-induced peripheral neuropathy. The awardee, Washington University, will utilize a SARM1 dominant-negative construct and virus-mediated overexpression of NAD+ salvage pathway enzymes to block the axon degeneration pathway activated by chemotherapeutic agents...
The National Institute on Aging (NIA) awarded a $589,106 Project Grant (CFDA 93.866 - Aging Research) to Washington University in St. Louis, Missouri, with a period of performance from June 1, 2025 to March 31, 2030. The grant supports research to elucidate the role of senescent stromal cells in driving chemotherapy-induced peripheral neuropathy (CIPN), a debilitating side effect experienced by up to 90% of cancer patients receiving taxane-based chemotherapies. The research aims to 1)...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) will fund a study to characterize the neuro-immune interactions in the skin of tumor-bearing mice with oxaliplatin-induced peripheral neuropathy (OIPN). The $426,960 award, with a project period from Sep 1, 2024 to Nov 30, 2026, will be performed by Wake Forest University Health Sciences. The study aims to (i) define how the cutaneous immune landscape is activated by tumor and repeated...